Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Active Ulcerative Colitis
NCT00261118Phase 3Completed
- Sponsor
- Royal Liverpool University Hospital
- Start
- Apr 2004
- Primary completion
- Aug 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ulcerative colitis (UC) comparing Rituximab + Prednisolone with Placebo + Prednisolone (2 arms). Primary endpoint: Clinical Remission at 4 weeks. Started Apr 2004; status: completed.
02
Drugs
rituximab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00261118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261118.